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A B S T R A C T
Purpose: The cytoprotective eﬀect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition is well documented in various
cell types subjected to oxidative stress. Previously, we have demonstrated that PARP1 inhibition activates Akt, and
showed that this response plays a critical role in the maintenance of mitochondrial integrity and in cell survival.
However, it has not yet been deﬁned how nuclear PARP1 signals to cytoplasmic Akt.
Methods: WRL 68, HeLa and MCF7 cells were grown in culture. Oxidative stress was induced with hydrogen peroxide.
PARP was inhibited with the PARP inhibitor PJ34. ATM, mTOR- and NEMO were silenced using speciﬁc siRNAs. Cell
viability assays were based on the MTT assay. PARP-ATM pulldown experiments were conducted; each protein was
visualized by Western blotting. Immunoprecipitation of ATM, phospho-ATM and NEMO was performed from cyto-
plasmic and mitochondrial cell fractions and proteins were detected by Western blotting. In some experiments, a
continually active Akt construct was introduced. Nuclear to cytoplasmic and mitochondrial translocation of phospho-
Akt was visualized by confocal microscopy.
Results: Here we present evidence for a PARP1mediated, PARylation-dependent interaction between ATM and NEMO,
which is responsible for the cytoplasmic transport of phosphorylated (thus, activated) ATM kinase. In turn, the cyto-
plasmic p-ATM and NEMO forms complex with mTOR and Akt, yielding the phospho-ATM-NEMO-Akt-mTOR signa-
losome, which is responsible for the PARP-inhibition induced Akt activation. The phospho-ATM-NEMO-Akt-mTOR
signalosome localizes to the mitochondria and is essential for the PARP-inhibition-mediated cytoprotective eﬀects in
oxidatively stressed cells. When the formation of the signalosome is prevented, the cytoprotective eﬀects diminish, but
cells can be rescued by constantly active Akt1, further conﬁrming the critical role of Akt activation in cytoprotection.
Conclusions: Taken together, the data presented in the current paper are consistent with the hypothesis that PARP
inhibition suppresses the PARylation of ATM, which, in turn, forms an ATM-NEMO complex, which exits the nucleus,
and combines in the cytosol with mTOR and Act, resulting in Act phosphorylation (i.e. activation), which, in turn,
produces the cytoprotective action via the induction of Akt-mediated survival pathways. This mechanism can be
important in the protective eﬀect of PARP inhibitor in various diseases associated with oxidative stress. Moreover,
disruption of the formation or action of the phospho-ATM-NEMO-Akt-mTOR signalosome may oﬀer potential future
experimental therapeutic checkpoints.
Abbreviations: ATM, ataxia telangiectasia mutated kinase; ATP, adenosine triphosphate; EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid; FBS, fetal bovine serum; H2O2, hydrogen peroxide; INT, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium
chloride; MAPK, mitogen-activated protein kinase; MEM, Eagle’s minimum essential medium; mTOR, mammalian target of rapamycin protein; MTT, 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NAD+, nicotinamide adenine dinucleotide; NEMO, NF-kappa-B essential modulator; PAR, poly(ADP-ribose);
PARP1, poly(ADP-ribose) polymerase 1; PIK, phosphatidylinositol 3-kinase; PBS, phosphate buﬀered saline; FCS, fetal calf serum; PJ34, N-(-oxo-5,6-dihydro-phe-
nanthridin-2-yl)-N,N-dimethylacetamide HCl; PMS, N-methylphenazonium methyl sulfate; PVDF, polyvinylidene ﬂuoride; RNS, reactive nitrogen species; ROS,
reactive oxygen species; SDS, sodium dodecyl sulfate
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1. Introduction
Poly(ADP-ribose)polymerase is activated by single strand DNA
breaks and catalyzes the covalent coupling of branched chains of ADP-
ribose (PAR) units to various nuclear proteins such as histone proteins
and PARP1 itself [1,2]. Consequently, PARP1 is involved in chromatin
remodeling, DNA repair, replication, transcription, and the main-
tenance of genomic stability [3,4]. Production of reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS) has a pivotal role in the
pathogenesis of various diseases including various forms of acute and
chronic inﬂammation and ischemia-reperfusion of the heart and brain
[3,5,6]. In these diseases, DNA strand breakage, induced by ROS/RNS,
leads to PARP1 over-activation. The classical pathway of PARP-medi-
ated cell injury stipulates that PARP overactivation, and, subsequent
depletion of PARP's substrate, NAD+ and, secondarily, the cellular
depletion of ATP leads to necrotic-type cell death [7–9]. Genetic deﬁ-
ciency, as well as pharmacological inhibition of PARP1 protects the
cells from cell death induced by oxidative or nitrosative stress. PARP
inhibitors have been demonstrated to exert signiﬁcant cytoprotective
eﬀects and preserve or improve organ function in animal models of
various pathophysiological conditions including myocardial ischemia
[10], neuronal ischemia [11,12], acute lung inﬂammation [13], septic
shock [14], multiple organ failure [15] and pancreatic damage during
the pathogenesis of diabetes [16–18].
Our previous studies demonstrated that besides preserving NAD+
and ATP levels [7], cytoprotective eﬀect of PARP inhibition is also
mediated via suppression of JNK and p38 mitogen-activated protein
kinases (MAPKs) [19–21], and phosphorylation – and thereby, activa-
tion – of Akt/PKB [9,22–24]. We have previously demonstrated that
PARP inhibition results in an increased expression and increased cy-
toplasmic localization of MAPK phosphatase-1 (MKP-1/Dusp1), and we
have presented evidence that this eﬀect is responsible for the afore-
mentioned cytoprotective eﬀects of PARP inhibitors [20]. In line with
the importance of the Akt pathway in PARP inhibitors’ cytoprotective
eﬀect, we have demonstrated that small-molecule Akt inhibitors
markedly reduce the protective eﬀect of PARP inhibitors in a model of
cardiac ischemia-reperfusion [22]. However, the exact molecular pro-
cesses that link the inhibition of PARP to the activation of the Akt/PKB-
mediated cytosolic survival pathway have not yet been elucidated.
PARP1 is involved in DNA base-excision repair [25] and homo-
logous recombination [26] by activating and attracting repair enzymes
to DNA breaks. Ataxia telangiectasia mutated kinase (ATM) participates
in homologous recombination and nonhomologous end-joining of DNA
double-stranded break repair [27]. Knockout experiments on ATM and
PARP1 have established that ATM knockout mice and PARP knockout
mice are viable, however, ATM-PARP double mutation leads to em-
bryonic lethality [28]. These observations have been utilized in a novel
tumor therapy where ATM deﬁciency sensitizes the tumor cells to a
PARP1 inhibitor [29], although the molecular mechanism of this syn-
thetic lethality is not well understood. Importantly, prior studies in-
vestigating the interrelationship between the PARP and the ATM
pathways have demonstrated that ATM is subject to PARP1-mediated
poly(ADP-ribosyl)ation [30,31].
The aim of this study was to deﬁne the molecular mechanisms, by
which the nuclear PARP1 can regulate the cytoplasmic phosphatidyli-
nositol 3-kinase (PI3K)-Akt pathway. The results presented in the cur-
rent report show that inhibition of PARP1 in oxidatively stressed cells
facilitates the export of ATM from the nucleus to the cytoplasm, which,
in turn, plays a role in the activation of Akt, and the subsequent cyto-
protective eﬀects, via the formation of a mitochondria-associated
phospho (p)-ATM-NEMO-Akt-mTOR cytoprotective signalosome.
2. Materials and methods
2.1. Cell lines
Human WRL 68 cells (a HeLa derivative line that exhibits a mor-
phology similar to hepatocytes and hepatic primary cultures]), HeLa
human cervix cancer cell line, MCF7 human breast adenocarcinoma
were obtained from the ATCC (Wesel, Germany). Cells were grown in
Eagle’s minimum essential medium (MEM) containing a 1% antibiotic-
antimycotic solution and 10% fetal calf serum (FCS) in a humid 5% CO2
atmosphere at 37 °C.
2.2. RNA interference
ATM-siRNA, mTOR-siRNA and NEMO-siRNA were purchased from
Santa Cruz Biotechnology. Transfection of WRL 68, MCF7 and HeLa
cells was performed with GeneJuice transfection reagent purchased
from NOVAGEN according to the protocol of manufacturer. Eﬃcacy of
the RNA interference was conﬁrmed with Western blotting using ap-
propriate primary antibodies.
2.3. Pharmacological inhibition of PARP
The PARP inhibitor PJ34 [N-(6-oxo-5,6-dihidro-phenanthridin-2-
yl)-N,N-dimethylacetamide] was purchased from Sigma, and was used
at 10 μM concentration. The concentration of PJ34 was selected based
on prior in vitro studies where the 10 μM PJ34 concentration was
proven to be eﬀective to inhibit cellular PARP activation and to produce
cytoprotective eﬀects under oxidative stress conditions [20,32].
2.4. Cell fractionation
Cells were cultured on a 10 cm dish, and treated with 0.3mM H2O2
(Sigma-Aldrich) for 3 h in the presence or absence of PJ34 (10 μM0,
rinsed in phosphate-buﬀered saline solution (PBS), pH 7.4. Afterwards,
the cells were harvested in 0.5ml ice-cold lysis buﬀer consisting of
20mM Tris pH 8.0, 10mM KCl, 2mM Mg2Cl, 1 mM EDTA and 1mM
EGTA and protease inhibitor cocktail (Sigma) and kept on ice for
15min. The cells were disrupted in a Teﬂon–glass homogenizer. The
nuclear fraction was pelleted at 750 g for 15min and retained for fur-
ther puriﬁcation. The supernatant was centrifuged at 10,000g for
15min, and the pellet was retained for puriﬁcation of mitochondrial
fraction. For cytosolic fraction, 200 μl aliquots of supernatant were
completed with 6× Sample Buﬀer (Laemmli) and stored at -80 °C until
immunoblot analysis of the cytosolic fraction. The nuclear pellet was re-
suspended in 1ml lysis buﬀer completed with 0.2% Triton X-100, re-
homogenized, and then centrifuged at 750g for 15min. The pellet was
resuspended in 100 μl Laemmli sample buﬀer and stored at -80 °C until
immunoblot analysis of the nuclear fraction. Mitochondrial pellet was
washed in 1ml Lysis buﬀer, then centrifuged at 10,000g for 15min.
Pellet was re-suspended in 100 μl Laemmli sample buﬀer and stored at
−80 °C until immunoblot analysis of the mitochondrial fraction. Cross-
contamination of the fractions were tested by immunoblotting utilizing
anti-Histone H3, anti-GAPDH and anti-cytochrome oxidase (C4) pri-
mary antibodies (data not shown).
2.5. Immunoblotting
Samples were homogenized in ice-cold isotonic Tris buﬀer (50mM, pH
8.0) containing 0.5mM sodium metavanadate, 1mM EDTA, and a pro-








Antigens were determined from the tissue homogenates after sonication.
Proteins were precipitated by trichloroacetate, washed three times with
−20 °C acetone, dissolved in Laemmli sample buﬀer, separated on 12%
SDS-polyacrylamide gels, and transferred to nitrocellulose membranes.
After the blocking phase (2 h with 3% nonfat milk in Tris-buﬀered saline),
the membranes were probed overnight at 4 °C with antibodies recognizing
the following antigens: anti-PARP1, anti-ATM, anti-p-ATM, anti-PAR, anti-
NEMO, anti-C4 (were from Santa Cruz Biotechnology), anti-Histone H3,
anti-GAPDH, anti-Akt, anti-p-Akt, anti-p-GSK3β, anti-mTOR, anti-His
(were from Cell Signaling Technology). The membranes were washed six
times for 5min in Tris-buﬀered saline (pH 7.5) containing 0.2% Tween
before addition of goat anti-rabbit horseradish peroxidase-conjugated
secondary antibody (1:3000 dilution; Bio-Rad). The protein bands were
visualized with enhanced chemiluminescence labelling using an ECL im-
munoblotting detection system (Amersham Biosciences). The developed
ﬁlms were scanned, and the pixel volumes of the bands were determined
using the NIH ImageJ software, with the values in ratios of intensity. Each
experiment was repeated a minimum of three times.
2.6. Cell viability assay
Viability of the WRL 68 cells was determined by colorimetric MTT
assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide,
Sigma-Aldrich) as described previously [20,32]. The cells were seeded
onto 96 plates at a density of 105cells/well and cultured overnight before
the experiment. After 24 h of treatment, the medium was removed and
fresh MEM/FCS containing 0.5% of the water-soluble yellow dye MTT was
added. The cells were then incubated for 3 h at 37 °C in an atmosphere of
5% CO2. After 3 h the medium was removed, and the water-insoluble blue
formazan dye formed stoichiometrically from MTT was solubilized by
acidic isopropanol (Sigma-Aldrich). Optical densities were determined by
a plate-reader (Anthos Labtech 2010) at the wavelength of 550 nm, and
the values were represented as arbitrary units. All experiments were run at
least in quadruplicates and repeated three times. The results are expressed
as percentages of control values.
2.7. Immunoprecipitation of ATM from mitochondrial or cytoplasmic cell
fractions
100 μl BioMag Goat Anti-Rabbit IgG beads (Bangs Laboratories)
were washed twice with PBS in magnetic rack than magnetic beads
were incubated with anti-ATM antibody (1:500 dilution in 3%BSA/PBS
buﬀer) for 2 h at room temperature in an orbital shaker. Then beads
were washed twice with PBS in a magnetic rack. Mitochondrial or cy-
toplasmic fractions were incubated with magnetic beads for 2 h at room
temperature in an orbital shaker. Magnetic beads were washed with
washing buﬀer 1 (20mM Tris pH=8.0, 150mM NaCl, 0.5% Triton X-
100), then with washing buﬀer 2 (20mM Tris pH=8.0, 150mM NaCl).
Beads were washed ﬁnally in washing buﬀer 3 (5mM Tris pH=8.0),
then the precipitated ATM was eluted with 1M ammonium-hydroxide.
The eluted fraction was lyophilized than precipitated and lyophilized
ATM was resolved in 100 μl 1× Laemmli sample buﬀer.
2.8. Cloning strategy of T308D-S473D-Akt: D2-Akt expression plasmid
T308D-S473D double mutant recombinant Akt gene was purchased
from GenCast Biotechnology. Transfection of WRL 68, MCF7 and HeLa
cells were performed with GeneJuice transfection reagent purchased
from NOVAGEN according to the protocol of manufacturer.
2.9. Fluorescent labeling of mitochondria with pDsRed-Mito plasmid
pDSRed-Mito plasmid was purchased from Clonetech. Transfection
of WRL 68, MCF7 and HeLa cells with pDsRed-Mito plasmid was per-
formed with GeneJuice transfection reagent purchased from NOVAGEN
according to the protocol of manufacturer. The cells were imaged using
Nikon Inverted Microscope Eclipse Ti-U using a 60× objective and
epiﬂuorescent illumination. The images were processed using Adobe
Photoshop CS5.
2.10. Immunocytochemistry
Wild type or transfected WRL 68 cells (pDsRedMito plasmid) were
seeded to poly-L-lysine-coated glass coverslips and cultured at least
overnight before the experiment. After subjecting the cells to the ap-
propriate treatment (indicated in the ﬁgure legends), the coverslips
were rinsed twice in PBS and then ﬁxed in 4% paraformaldehyde at 4 °C
for 20min. Cells were permeabilized with 0.5% Triton-X100 in PBS at
room temperature for 10min, then cells were rinsed three times in PBS.
Afterwards the cells were incubated with 10% BSA in PBS for 40min at
room temperature to block unspeciﬁc binding of antibodies. WRL 68
cells were incubated with p-ATM (1:100 dilution) primary antibodies
diluted in 10% BSA in PBS for 1 h at room temperature. Following three
times PBS washing the cells were incubated with the anti-rabbit Alexa
Fluor 488 secondary antibody (1:200 dilution, Life Technologies) in
10% BSA in PBS for 1 h at room temperature in dark. The cells were
washed three times in PBS prior to mounting in Vectashield Mounting
Medium with DAPI (Vector Laboratories). The cells were imaged using
Nikon Inverted Microscope Eclipse Ti-U using a 60× objective and
epiﬂuorescent illumination. The images were processed using Adobe
Photoshop CS5.
2.11. Statistics
All data are expressed as means ± SEM from replicate determina-
tions. ANOVA with a post hoc correction was used to determine dif-
ferences. Student’s t test was used to compare the mean values from the
two groups. Diﬀerences were regarded as signiﬁcant at p < 0.05.
3. Results
3.1. Eﬀect of PARP inhibition on cell survival and Akt activation in
oxidative stress
Previously, we reported that PARP inhibition increased survival of
WRL68 cells in oxidative stress, and activation of Akt was signiﬁcantly
involved in this protective eﬀect [9]. In the present study, we reproduced
these results by using PJ34, the inhibitor we used in the previous report, at
diﬀerent concentrations. Oxidative stress was induced by exposing the
cells to 0.3mM H2O2 for 3 h. Viability was measured by the MTT assay
while Akt activation was assessed by immunoblotting using anti p-Ser473-
Akt primary antibody. In agreement with the previous results, PJ34 did
not aﬀect viability of the control cells at the concentrations tested, and
markedly reduced oxidative stress induced cell death (Fig. 1A) and ele-
vated Akt phosphorylation (Fig. 1B) at concentrations above 1 μM. We
examined the eﬀect of PARP inhibition on 1.5mM sodium nitroprusside
(SNP) induced stress besides the H2O2 induced one. In these experiments
we tested two additional PARP inhibitors recently approved for human
clinical practice of cancer therapy; olaparib and veliparib as well as PARP1
silencing by using speciﬁc siRNA technique (Fig. 2). Olaparib, veliparib
and PARP1 silencing reduced both H2O2− (Fig. 2A) and SNP (Fig. 2B)
induced cell death and enhanced Akt phosphorylation (Fig. 2) both in the
presence and absence of oxidative-nitrosative stress in about the same
extent as PJ34 did.
3.2. Interaction between ATM and PARP1 in oxidative stress
Since PARP1 was reported to PARylate itself as well as to PARylate
ATM during oxidative stress [30,31], we hypothesized an interaction
between these two proteins. To test whether an interaction between
PARP1 and ATM exists in cells subjected to oxidative stress, we ex-








subjected to 0.3 mM of H2O2 in the presence or absence of 10 μM of
PJ34. Three hours later, recombinant Myc-tagged PARP1 was pulled-
down by anti-myc antibody immobilized to anti-rabbit secondary an-
tibodies conjugated to magnetic beads. PARP1 and ATM were visua-
lized by immunoblotting utilizing anti-PARP1 and anti-ATM primary
antibodies. The experiments revealed an interaction between PARP and
ATM; this interaction markedly increased in response to H2O2 and was
diminished by PJ34 (Fig. 3A). PJ34 alone did not aﬀect the low-level
basal PARP1- ATM interaction that was detected in the absence of
oxidative stress (Fig. 1A). Although, when activated, PARP1 PARylates
itself as well as ATM [30,31], electrostatic repulsion between the ne-
gatively charged PAR-residues cannot explain these results, indicating
that other factors must be involved in the PARP1-ATM interaction.
Next, we investigated whether PARP1 activity modulates the in-
tracellular distribution of ATM. To this end, we treated wild type
WRL68 cells as above, and visualized ATM from the cytoplasmic and
the nuclear fraction of the cells by immunoblotting using an anti-ATM
primary antibody. We observed that the oxidative stress decreased the
cytosolic ATM levels, an eﬀect that was diminished by PARP1 inhibi-
tion (Fig. 3B). PJ34 itself did not have any signiﬁcant eﬀect on the
Fig. 1. Eﬀect of PJ34 on cell survival and Akt activation in oxidative stress.
WRL-68 cells were treated (light bars) or not (dark bars) with 0.3mM H2O2 for
3 h in the presence or absence of diﬀerent concentrations of PJ34 as indicated.
Cell viabilities (A) were determined by MTT assay and expressed as % vi-
abilities of the untreated wild type cells, means ± S.E.M. of three independent
experiments. In a parallel experiment of the same treatment protocol, the cell
homogenates were subjected to immunoblotting (B) utilizing anti-p-Akt pri-
mary antibody. The results are presented as representative blots as well as pixel
densities of the bands, means+ S.E.M. of three independent experiments.
GAPDH was used as a loading control. Signiﬁcantly diﬀerent groups (p < 0.05)
are indicated by lower case letters above the bars.
Fig. 2. Eﬀect of PJ34, olaparib, veliparib and PARP1 silencing on cell survival
and Akt activation in oxidative and nitrosative stress. WRL-68 cells were
transfected with a PARP1siRNA expressing plasmid. Wild type and the trans-
fected cells were treated with 0.3mM H2O2 (A) or 1.5mM SNP (B) for 3 h in the
presence or absence of 10 μM PJ34, 100 nM olaparib or 100 nM veliparib as
indicated. Cell viabilities were determined by MTT assay and expressed as %
viabilities of the untreated wild type cells, means ± S.E.M. of three in-
dependent experiments. In a parallel experiment of the same treatment pro-
tocol, the cell homogenates were subjected to immunoblotting utilizing anti-p-
Akt primary antibody. The results are presented as representative blots as well
as pixel densities of the bands, means+ S.E.M. of three independent experi-
ments. GAPDH was used as a loading control. Signiﬁcantly diﬀerent groups
(p < 0.05) are indicated by lower case letters above the bars. The treatment
protocols are indicated above the representative blots, but apply to viability and








amount of cytoplasmic ATM detected (Fig. 3B). No signiﬁcant diﬀer-
ences in nuclear ATM were detected in the four experimental conditions
utilized (Fig. 3B). These ﬁndings are consistent with the hypothesis (but
does not prove) that the PARP-ATM interaction detected in Fig. 3A
results in the translocation of a portion of the cellular ATM from the
cytosol to the nucleus.
3.3. PARP1 inhibition results in an interaction between ATM and NEMO
Previous studies demonstrated that NEMO is responsible for the nu-
clear export of ATM [33]. To determine whether an interaction also exists
between ATM and NEMO (and whether this interaction is modulated by
oxidative stress and PARP1 activity), we employed an experimental design
Fig. 3. Interaction of ATM, PARP1 and NEMO in WRL68 cells in oxidative stress. Myc-tagged PARP1 was overexpressed in WRL68 cells, and the cells were treated
with 0.3mM H2O2 for 3 h in the presence or absence of the pharmacological PARP1 inhibitor PJ34 as indicated. Recombinant Myc-tagged PARP1 was pulled-down
by anti-Myc magnetic beads, then PARP1 and ATM were determined by immunoblotting (A) utilizing anti-PARP1 and anti-ATM primary antibodies from the
solubilized precipitate. In a parallel experiment, wild type WRL 68 cells were subjected to the same treatment protocol. ATM levels in cytosolic and nuclear fraction
of the cells (B) were determined by immunoblotting utilizing anti-ATM primary antibody. Using a separate batch of treated cells, ATM was pulled-down by anti-ATM
magnetic beads, then ATM and NEMO (C) were determined by immunoblotting utilizing anti-ATM and anti-NEMO primary antibodies from the solubilized pre-
cipitate. PARylation of ATM was demonstrated by immunoblotting utilizing anti-PAR primary antibody. The results are presented as representative blots as well as
pixel densities of the bands, means+ S.E.M. of three independent experiments. GAPDH and PARP1 were used as loading controls, as indicated. Signiﬁcantly diﬀerent
















similar to the one used for detecting PARP1-ATM interaction, with ap-
propriate modiﬁcations. We pulled-down ATM by an anti-ATM antibody
immobilized to anti-rabbit secondary antibodies conjugated to magnetic
beads, and subsequently determined ATM and NEMO from the precipitate
by immunoblotting utilizing anti-ATM and anti-NEMO primary antibodies.
In contrast to the PARP1-ATM interaction, ATM-NEMO co-precipitation
was close to the detection limit both under basal and oxidative stress
conditions (Fig. 3C). The PARP inhibitor signiﬁcantly increased the ATM-
NEMO interaction in control cells (in the absence of oxidative stress); this
eﬀect was however markedly more pronounced during oxidative stress
(Fig. 3C). These data are consistent with the hypothesis that PARP1 cat-
alytic activity has a functional role in the NEMO-mediated nuclear-to-cy-
toplasmic export of ATM.
3.4. PARP1 inhibitor induces export of phospho (p)-ATM from the nucleus
Activation of ATM involves autophosphorylation (Ser1981) and dis-
sociation to monomers, followed by further autophosphorylation
(Ser367, Ser1893) [34]. To determine whether the subcellular distribu-
tion of p-ATM is regulated by PARP activity in cells subjected to oxi-
dative stress, WRL-68 cells were treated with 0.3 mM H2O2 for 3 h in
the presence or absence of 10 μM PJ34. Subsequently, immunoblotting
was performed using anti-p-ATM and anti-NEMO primary antibodies
from nuclear and cytoplasmic extracts of the cells. Phosphorylation of
ATM in the nuclear fraction was increased in H2O2 treated cells, both in
the presence and absence of the PARP inhibitor (Fig. 4A: p-ATM, Nucl.).
Thus, oxidative stress induces ATM phosphorylation, and this process is
independent of PARP's catalytic activity. Importantly, a signiﬁcant
amount of phosphorylated ATM translocated to the cytoplasmic frac-
tion in oxidatively stressed cells, and this eﬀect was markedly enhanced in
the presence of the PARP inhibitor (Fig. 4A: p-ATM, Cyt.). We also de-
termined intracellular distribution of NEMO, the interacting partner of
ATM [33]. Nuclear NEMO level was increased in oxidative stress while
the PARP1 inhibitor diminished it both in control cells and in cells
subjected to oxidative stress (Fig. 4A: NEMO, Nucl.). Cytoplasmic
NEMO levels followed a pattern that was complementary to that of the
nuclear fraction (Fig. 4A: NEMO, Cyt.).
Next, we sought to determine the intracellular localization of pATM
translocated from the nucleus due to PARP1 inhibition during oxidative
stress. To this end, WRL-68 cells were transfected with pDsRedMito ex-
pression plasmid that directs red ﬂuorescence to the mitochondria. The
transfected cells were treated with 0.3mM H2O2 for 3 h in presence or
absence of 10 μM PJ34, ﬁxed, permeabilized, stained with anti-p-ATM
primary and anti-rabbit Alexa Fluor 488 secondary antibodies, then ana-
lyzed by confocal microscopy. In agreement with the immunoblot results,
we observed faint green ﬂuorescence in the untreated or PJ34 treated cells.
Oxidative stress induced a marked enhancement of the green ﬂuorescence
that was located to the nucleus, while the ﬂuorescence spread to the whole
cell when the cell was also co-treated with PJ34 (Fig. 4B). DAPI counter-
staining (blue) helped in visualization of the cells. At higher magniﬁcation
(Fig. 4C), red mitochondria located ﬂuorescence dominated the merged
images in control conditions (in the absence of oxidative stress). Oxidative
stress induced the phosphorylation of ATM, as indicated by intense green
ﬂuorescence that was localized to the nucleus in the absence of PJ34, but
was present in the whole cell in the presence of PJ34 (Fig. 4C). In the latter
case, p-ATM appeared mostly to co-localize with the red mitochondria, as
indicated by the orange color in the merged image (Fig. 4C).
3.5. Co-precipitation of Akt, mTOR and NEMO with p-ATM
The above data demonstrate that PARP1 inhibition under oxidative
stress conditions activates the cytoplasmic transport of p-ATM. The data
are also consistent with published data [33] showing that the cyto-
plasmic transport of p-ATM occurs in a NEMO-dependent manner. The
above observations raise the possibility of an extra-nuclear signalosome
formation. To examine whether such a signalosome, indeed, may exist,
we immunoprecipitated p-ATM from cytosolic and mitochondrial
fractions of WRL 68 cells treated with 0.3mM H2O2 for 3 h in presence
or absence of 10 μM PJ34, and detected the co-precipitated proteins by
immunoblotting utilizing anti-p-ATM, anti-Akt, anti-mTOR and anti-
Fig. 4. Altered subcellular distribution of p-ATM and NEMO caused by PARP inhibition in oxidative stress. WRL-68 cells were treated with 0.3mM H2O2 for 3 h in the
presence or absence of PJ34 as indicated. Cytoplasmic (Cyt. and light bars) and nuclear (Nucl. and dark bars) fraction of the cells were subjected to immunoblotting
(A) utilizing anti-phospho (p)-ATM and anti-NEMO primary antibodies. The results are presented as representative blots as well as pixel densities of the bands,
means+ S.E.M. of three independent experiments. GAPDH and histone H3 were used as loading controls, as indicated. Signiﬁcantly diﬀerent groups (p < 0.05) are
indicated by lower case letters above the bars. The numbers above the blots indicate the treatment protocol of the groups in the bar diagram. In a parallel experiment,
WRL-68 cells were treated as above. After the treatment, immunocytochemistry and confocal ﬂuorescent microscopy were performed on the ﬁxed and permeabilized
cells utilizing anti-p-ATM primary and anti-rabbit-Alexaﬂuor488 secondary antibodies. Nuclei were counterstained by DAPI. The results are presented as re-
presentative images (B) of three independent experiments from the green as well as the merged green and blue channels. Alternatively, mitochondria were labelled
(red) by transfecting WRL-68 cells with pDsRedMito expression plasmid before the cells were exposed to the same treatment protocol. After the treatment, im-
munocytochemistry and confocal ﬂuorescent microscopy were performed on the ﬁxed and permeabilized cells utilizing anti-p-ATM primary and anti-rabbit-
Alexaﬂuor488 secondary antibodies. The results are shown as representative images (C) of three independent experiments from the green and red channels. For
indicating co-localization, merged images of green and red ﬂuorescence of the same ﬁeld are also demonstrated. Mito. denotes mitochondrial staining.
Fig. 5. Proteins co-immunoprecipitating with p-ATM from subcellular fractions
of WRL-68 cells in oxidative stress and PARP1 inhibition. WRL-68 cells were
treated with 0.3mM H2O2 for 3 h in the presence or absence of PJ34 as in-
dicated, then p-ATM was pulled-down by anti-p-ATM magnetic beads from
cytoplasmic and mitochondrial fractions of the cells. Solubilized precipitates
were subjected to immunoblotting utilizing anti-p-ATM, anti-Akt, anti-mTOR
and anti-NEMO primary antibodies. The results are presented as representative









NEMO primary antibodies. The results show that Akt, mTOR and NEMO
all co-precipitate with p-ATM in the cytosolic and mitochondrial frac-
tions, but this interaction is only detectable in the cells that were
treated by PJ34 as well as H2O2 (Fig. 5) supporting the existence of a
signalosome comprising p-ATM, mTOR, AKT and NEMO, the formation
of which is regulated by PARP catalytic activity, and which is, at least
partially, associated with the mitochondria.
3.6. Silencing of the various signalosome components impairs the
cytoprotective eﬀect of PARP1 inhibition
To assess the functional signiﬁcance of the above signalosome in
mediating the cytoprotective eﬀect of PARP inhibition, we system-
atically silenced its putative components (ATM, NEMO and mTOR) by
using siRNA technique. For eliminating cell-speciﬁc eﬀects, we used
human HeLa cervix cancer and MCF7 breast carcinoma cell lines in
addition to the WRL-68 line in these experiments. Eﬃcacy of gene si-
lencing of the target proteins was conﬁrmed in all three cell lines by
immunoblotting utilizing anti-ATM, anti-NEMO and anti-mTOR pri-
mary antibodies (Fig. 6A). The ATM-, NEMO- or mTOR silenced and
wild type control cells were treated with 0.3 mM H2O2 for 3 h in the
presence or absence of 10 μM PJ34, then viability was determined by
the MTT assay. We observed signiﬁcant cytoprotective eﬀect of the
PARP inhibitor in all three cell lines. However, this cytoprotective eﬀect
was abolished by ATM, NEMO, or mTOR silencing (Fig. 6B). These data
indicate that cytoprotective eﬀect of PARP inhibition in oxidatively
stressed cells, is, indeed, mediated by the cytosolic translocation of the
p-ATM-NEMO complex and also suggests that an interaction with
mTOR is also functionally important. Taken together, the above data
are consistent with a working model where, in oxidatively stress cells,
the PARP-inhibition-induced activation of the cytoprotective p-AKT-
mTOR cytosolic pathway is the consequence of a nuclear signal, which
originates from the prevention of the PARylation of nuclear ATM, ex-
ternalizes from the nucleus to the cytosol by p-ATM-NEMO and signals
to downstream eﬀector(s), at least in part via a process that also in-
volves a mitochondrial interaction.
3.7. The role of ATM, NEMO, and mTOR in Akt phosphorylation
To determine the role of ATM, NEMO and mTOR in the activation of
the Akt pathway, silenced and wild type WRL68, HeLa and MCF7 cells
were treated with 0.3 mM H2O2 for 3 h in the presence or absence of
10 μM PJ34. The cellular proteins were subjected to immunoblotting
using anti p-Ser473-Akt primary antibody. In the wild type cells, we
observed a faint baseline phosphorylation of Akt that was increased by
either H2O2 or PJ34. However, when both H2O2 and PJ34 were present
in the medium, phosphorylation thereby activation of Akt was mark-
edly enhanced (Fig. 6C). This markedly elevated Akt phosphorylation
was abolished by silencing ATM, NEMO or mTOR (Fig. 4C). These re-
sults conﬁrm that formation of the aforementioned signalosome could
account for the PARP-inhibition induced activation of the cytoprotec-
tive p-AKT-mTOR cytosolic pathway.
3.8. When the assembly of the ATM-NEMO-mTOR-Akt signalosome is
prevented, a continuously active recombinant Akt (T308D-S473D-Akt:
D2Akt) restores a cytoprotective phenotype
To assess the functional importance of Akt activation due to PARP
inhibition in oxidative stress, we constructed a plasmid expressing
continuously active Akt (D2Akt) that was His-tagged for enabling de-
termination of its expression level. We transfected WRL68 cells with
ATM-siRNA and/or D2Akt expressing plasmids in diﬀerent combina-
tions. Then, we treated the cells with 0.3mM H2O2 for 3 h in the pre-
sence or absence of 10 μM PJ34. Cell viability was detected by MTT
assay, while whole cell extracts from a parallel experiment were sub-
jected to immunoblotting utilizing anti-p-Akt and anti-His primary
antibodies for determining phospho-Akt and D2Akt levels, and anti-p-
GSK3β primary antibody for conﬁrming Act activation (since GSK3β is
a downstream target of Akt).
Recombinant D2Akt did not have any eﬀect on cell survival either in
baseline conditions (in the absence of oxidants) or during oxidative
stress (Fig. 7A). In contrast, PJ34 protected against the oxidative stress
induced loss of cell viability; this cytoprotective eﬀect was signiﬁcantly
diminished by ATM silencing. However, in cells expressing D2Akt, a
cytoprotective phenotype was preserved, even when ATM was silenced
(and therefore the formation of the signalosome was no longer allowed)








(Fig. 7A). This result suggests that activation of Akt is downstream from
PARP inhibition and signalosome formation and can be viewed as a
distal regulator of cell survival in oxidatively stressed cells. The ob-
served patterns of both D2Akt expression and GSK3β phosphorylation
(indicator of Akt activation) (Fig. 7B) are fully consistent with this
view. His-tagged Akt was present only in lanes 6 and 7 that was ac-
companied with increased phospho-Akt levels and markedly enhanced
phosphorylation of GSK3β in these lanes (Fig. 7B), while faithfully re-
ﬂecting Akt activation, GSK3β phosphorylation was faint in untreated
baseline controls (lane 1), strengthened under PARP1 inhibition in
control cells (without oxidative stress) (lane 4) or cells subjected to
oxidative stress (lane 2), and was even more pronounced when PARP1
was inhibited in oxidatively stressed cells (lane 3). The latter response
was diminished by ATM-siRNA (lane 5), while ATM-siRNA alone (lane
8) did not aﬀect GSK3β phosphorylation (Fig. 7B).
Fig. 6. Silencing of ATM, NEMO or mTOR abolishes the cytoprotective eﬀect of
PARP1 inhibition in oxidative stress. WRL68 (light bars), HeLa (grey bars) and
MCF (dark bars) cells were transfected with ATM-siRNA-, NEMO-siRNA or
mTOR-siRNA expressing plasmids as indicated. Wild-type and the transfected
cells were treated with 0.3mM H2O2 for 3 h in the presence or absence of PJ34
as indicated. Eﬃcacy of gene-silencing (A) was checked by immunoblotting
utilizing anti-ATM, anti-NEMO and anti-mTOR primary antibodies and de-
monstrated as representative blots of three independent experiments. Cell vi-
abilities (B) were determined by MTT assay and expressed as % viabilities of the
untreated wild type cells, means ± S.E.M. of three independent experiments.
P-Akt levels of the cells (C) were determined by immunoblotting utilizing anti-
p-Akt primary antibody and presented as representative blots as well as pixel
densities of the bands, means+ S.E.M. of three independent experiments.
Untreated control, H2O2 only, H2O2+ PJ34 and PJ34 only groups are indicated
as black, dark grey, light grey and white bars, respectively. Signiﬁcantly dif-
ferent groups (p < 0.05) are indicated by lower case letters above the bars.
Fig. 7. Continuously active recombinant Akt (T308D-S473D-Akt: D2Akt) counteract ATM silencing’s deleterious eﬀect on PARP inhibition induced cytoprotection.
WRL-68 cells were transfected with ATM-siRNA and C-terminal-polyHis tagged D2Akt expressing plasmids in diﬀerent combinations as indicated. Wild type and the
transfected cells were treated with 0.3mM H2O2 for 3 h in the presence or absence of PJ34 as indicated. Cell viabilities (A) were determined by MTT assay and
expressed as % viabilities of the untreated wild type cells, means ± S.E.M. of three independent experiments. In a parallel experiment of the same treatment
protocol, the cell homogenates were subjected to immunoblotting (B) utilizing anti-p-Akt, anti-His and anti-p-GSK3β (downstream target of Akt) primary antibodies.
The results are presented as representative blots as well as pixel densities of the bands, means+ S.E.M. of three independent experiments. GAPDH was used as a
loading control. Signiﬁcantly diﬀerent groups (p < 0.05) are indicated by lower case letters above the bars. The numbers above the blots indicate the treatment









PARP inhibitors are now clinically used for cancer therapy
[33,34,35], but there is also a second line of evidence indicating their
potential utility in various non-oncological diseases, many of which are
associated with the overproduction of ROS and RNS, which, in turn,
induces deleterious PARP overactivation; under these conditions PARP
inhibitors exert cytoprotective and anti-inﬂammatory eﬀects (4). In the
context of cancer therapy, cytoprotective eﬀects of PARP inhibitors may
limit their eﬃcacy as anticancer agents [35]. Namely, PARP inhibition
can regulate kinase cascades such as PI3K-Akt [9,24] and MAPK
[20,21] pathways, and protect mitochondrial membrane integrity
[36–38]. Previously, we reported that a PARP1-ATF4-MKP1-MAPK
retrograde signaling pathway is involved in the MAPK downregulating
eﬀect of PARP1 inhibition [20,32]. In the present study, we found that
above the concentration of 1 μM, PJ34 diminished H2O2 induced death
of WRL68 cells, and increased Akt activation (Fig. 1). Additionally,
olaparib and veliparib, the PARP inhibitors used in human clinical
practice of cancer therapy, as well as PARP1 silencing protected the
cells against H2O2 and SNP induced stress while enhanced Akt activa-
tion in about the same extent as PJ34 did (Fig. 2). These results con-
ﬁrmed previous ﬁndings by us [9] and others [39–41], and underline
the signiﬁcance of Akt activation in PARP inhibition’s protective eﬀect
in various disease models [3,22,42–44]. Therefore, in the present study
we made an eﬀort to understand the yet elusive molecular mechanism
connecting PARP inhibition and Akt activation.
ATM was reported to be involved in the phosphorylation and acti-
vation of Akt in some cancer cell lines, in insulin treated myocytes, and
under cellular stress conditions [45–47]. A defect in ATM-mediated Akt
activation was indicated as a signiﬁcant factor in the development of
diabetes and neurodegenerative diseases, and ATM was suggested as a
therapeutic target in cancer [47]. Additionally, PARP1 was found to
PARylate ATM [30,31]. Consequently, we investigated whether a
PARP1-ATM interaction is present in oxidatively stressed cells. We have
utilized the WRL 68 cell line, which was used previously to demonstrate
the importance of PARP1 inhibition in Akt activation [9]. Consistent
with these ﬁndings, we observed that pharmacological inhibition of
PARP1 stimulated the nuclear-to-cytosolic translocation of ATM, and it
also enhanced a PARP1-ATM interaction both in control cells and
during oxidative stress (Fig. 3A, B). Furthermore, the data presented in
the current report demonstrate that inhibition of the oxidative stress-
induced PARylation of ATM promotes the association of phosphory-
lated (and, therefore, active) ATM with NEMO (Fig. 3C). Following
their cytosolic translocation, we have presented evidence for the for-
mation of a p-ATM-NEMO-Akt-mTOR signalosome (Fig. 5). By two se-
parate methods (Figs. 4C and 5), we demonstrated that this signalosome
was, at least partially, localized to the mitochondria; an excellent po-
sition to exert mitochondria protecting eﬀect of the PARP1 inhibition in
oxidative stress. The data presented in the current report are consistent
with the crucial importance of Akt activation in PARP1’s cytoprotective
eﬀect: both cytoprotection and phosphorylation of Akt’s downstream
target, GSK3β are preserved when continuously active Akt was ex-
pressed in ATM silenced cells while ATM silencing itself abolished these
eﬀects (Fig. 7). Finally, the data are consistent with the hypothesis that
the aforementioned signalosome is involved in mediating PARP1’s ex-
tranuclear eﬀects (Fig. 6), since silencing any of its components abol-
ished Akt-activating and cytoprotective eﬀect of the PARP1 inhibitor.
Although all three human cell lines we used for these experiments are of
tumor origin, the uniform results suggest that aforementioned role of
the p-ATM-NEMO-Akt-mTOR signalosome may be universal.
PARP1 inhibition was reported to induce synthetic lethality in ATM
suppressed or mutated cells [29], although molecular mechanism of
this eﬀect remained unclear. Apparently, inactivation of these two
DNA-repair enzymes is lethal. However, in this study, we presented
evidence that although suppression of ATM together with PARP in-
hibition caused cell death, overexpression of the active mutant T308D-
S473D-Akt1 can rescue these cells (Fig. 7). These data indicate that the
synthetic lethality of ATM-suppressed or ATM-mutated cells induced by
PARP1 inhibitor is predominantly due to the lack of Akt1 activation.
These data provide a mechanistic basis for and emphasize the sig-
niﬁcance of using PARP inhibitors in combination with PI3K-Akt in-
hibitors for tumor therapy. PARP1 inhibitors promote cell death by
inhibiting DNA repair leading to lethal accumulation of mutations in
the rapidly proliferating tumor cells. They are most eﬀective in tumors
having deleterious mutations in other DNA repair systems; therefore
PARP1 inhibitors are used as a monotherapy in BRCA mutations car-
rying cancers [48]. However, the PARP-inhibitor-induced activation of
the cytoprotective PI3K-Akt pathway in oxidatively stressed cells can
cause cytostatic resistance undermining its cytostatic eﬀect [35]. Some
reports support this notion by demonstrating increased cytostatic eﬃ-
cacy of PARP1 inhibitors when used in combination with Akt inhibitors
[35,49,50].
In conclusion, we presented evidence for a regulatory role of PARP1
in inducing a nuclear-to-cytosolic transport of phosphorylated ATM
kinase. This process initiates in the nucleus by oxidative stress induced
double-stranded DNA breaks, which, in turn, induces PARP activation,
and the PARylation of ATM. In parallel, oxidative stress also induces a
PARP-independent phosphorylation of ATM. In turn, the results are
consistent with the formation of a p-ATM-NEMO-Akt-mTOR signalo-
some. This signalosome is, at least partially, localized to the mi-
tochondria, and appears to play a pivotal role in Akt activation and
protection against oxidative-stress-related cell death (Fig. 8). Ad-
ditionally, the data presented in the current report suggest that ATM
deﬁciency and PARP inhibition-dependent synthetic lethality is the
consequence of lacking Akt activation, providing a theoretical basis for
combining Akt inhibition with PARP inhibition in the context of tumor
therapy.
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Fig. 8. A working model of the mode of PARP1 inhibition’s molecular me-
chanism of Akt activation and cell survival in oxidatively stressed cells. PARP
inhibition increases p-ATM-NEMO interaction, thereby facilitating cytoplasmic
translocation of the p-ATM-NEMO complex, and the consequent formation of
the p-ATM-NEMO-Akt-mTOR cytoprotective signalosome. Assembly of the
signalosome leads to Akt activation, which, in turn, activates various cell sur-
vival. pathways Arrows with pointed and ﬂat end represent activation and in-
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